{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:09Z","timestamp":1792103829101,"version":"4.4.0"},"reference-count":43,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2024.12387","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T01:19:57Z","timestamp":1705281597000},"source":"Crossref","is-referenced-by-count":9,"title":["Effect of metabolic dysfunction\u2011associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta\u2011analysis"],"prefix":"10.3892","volume":"27","author":[{"given":"Sixing","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"key20240227085737_b1-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","article-title":"Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv Cancer Res"},{"key":"key20240227085737_b2-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"key20240227085737_b3-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.4254\/wjh.v7.i8.1064","article-title":"Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogu","volume":"7","author":"Rapti","year":"2015","journal-title":"World J Hepatol"},{"issue":"S45","key":"key20240227085737_b4-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00811-2","article-title":"Hepatitis B","volume":"603","author":"Brody","year":"2022","journal-title":"Nature"},{"key":"key20240227085737_b5-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"key20240227085737_b6-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","article-title":"Molecular mechanisms of viral oncogenesis in humans","volume":"16","author":"Krump","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"111","key":"key20240227085737_b7-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6120111","article-title":"Viral oncology: Molecular biology and pathogenesis","volume":"6","author":"Mui","year":"2017","journal-title":"J Clin Med"},{"issue":"63","key":"key20240227085737_b8-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"20420188221145549","key":"key20240227085737_b9-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: A multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"key20240227085737_b10-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"128","DOI":"10.14218\/JCTH.2021.00200","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis","volume":"10","author":"Wang","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"100350","key":"key20240227085737_b11-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100350","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B","volume":"3","author":"van Kleef","year":"2021","journal-title":"JHEP Rep"},{"key":"key20240227085737_b12-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/DMSO.S351492","article-title":"MAFLD is associated with the risk of liver fibrosis and inflammatory activity in HBeAg-negative CHB patients","volume":"15","author":"Chen","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"n71","key":"key20240227085737_b13-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"45","key":"key20240227085737_b14-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: Comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"ED000142","key":"key20240227085737_b15-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"e8109","key":"key20240227085737_b16-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2021.02.8109","article-title":"The GRADE approach, Part 1: How to assess the certainty of the evidence","volume":"21","author":"Kirmayr","year":"2021","journal-title":"Medwave"},{"key":"key20240227085737_b17-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3350\/cmh.2018.0040","article-title":"Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"key20240227085737_b18-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B","volume":"32","author":"Chan","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"key20240227085737_b19-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-021-10205-7","article-title":"Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy","volume":"15","author":"Oh","year":"2021","journal-title":"Hepatol Int"},{"key":"key20240227085737_b20-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ijc.34637","article-title":"Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients","volume":"153","author":"Kim","year":"2023","journal-title":"Int J Cancer"},{"key":"key20240227085737_b21-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","article-title":"Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B","volume":"17","author":"Huang","year":"2023","journal-title":"Hepatol Int"},{"key":"key20240227085737_b22-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/JHC.S355540","article-title":"Impact of PNPLA3 p. I148M and hepatic steatosis on long-term outcomes for hepatocellular carcinoma and HBsAg seroclearance in chronic hepatitis B","volume":"9","author":"Hsueh","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"key20240227085737_b23-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3350\/cmh.2018.0054","article-title":"Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"key20240227085737_b24-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","article-title":"Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load","volume":"1","author":"Peleg","year":"2019","journal-title":"JHEP Rep"},{"issue":"6012","key":"key20240227085737_b25-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14236012","article-title":"Metabolic-associated fatty liver disease, hepatitis B surface antigen seroclearance, and long-term risk of hepatocellular carcinoma in chronic hepatitis B","volume":"14","author":"Yu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20240227085737_b26-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/jvh.13594","article-title":"No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B","volume":"28","author":"Chang","year":"2021","journal-title":"J Viral Hepat"},{"key":"key20240227085737_b27-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"issue":"1178636120918878","key":"key20240227085737_b28-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.1177\/1178636120918878","article-title":"Presence of hepatic steatosis does not increase the risk of hepatocellular carcinoma in patients with chronic hepatitis b over long follow-Up","volume":"13","author":"Lim","year":"2020","journal-title":"Microbiol Insights"},{"key":"key20240227085737_b29-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14218\/JCTH.2022.00055","article-title":"Prognostic relevance of metabolic dysfunction-associated steatohepatitis for patients with chronic hepatitis B","volume":"11","author":"Rugivarodom","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"key20240227085737_b30-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/MCG.0000000000001217","article-title":"Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B","volume":"54","author":"Cho","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"key20240227085737_b31-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","article-title":"Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection","volume":"15","author":"Mak","year":"2021","journal-title":"Hepatol Int"},{"key":"key20240227085737_b32-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/MEG.0000000000002583","article-title":"The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: A propensity score matching study","volume":"35","author":"Wang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20240227085737_b33-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","article-title":"Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis b surface antigen seroclearance in chronic hepatitis B","volume":"224","author":"Li","year":"2021","journal-title":"J Infect Dis"},{"issue":"641","key":"key20240227085737_b34-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050641","article-title":"Chronic inflammation-A link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue","volume":"58","author":"Petrescu","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"key20240227085737_b35-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.7150\/ijbs.47143","article-title":"Kupffer cells in non-alcoholic fatty liver disease: Friend or foe?","volume":"16","author":"Chen","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"4156","key":"key20240227085737_b36-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"91","key":"key20240227085737_b37-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11010091","article-title":"Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease","volume":"11","author":"Ma","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"3570","key":"key20240227085737_b38-ETM-27-3-12387","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103570","article-title":"Adipokines and obesity. Potential link to metabolic disorders and chronic complications","volume":"21","author":"Zorena","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20240227085737_b39-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1097\/MCG.0000000000000391","article-title":"Role of gut microbiota in liver disease","volume":"49 (Suppl 1)","author":"Brenner","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"key20240227085737_b40-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"244","DOI":"10.20524\/aog.2023.0793","article-title":"Innate immunity and nonalcoholic fatty liver disease","volume":"36","author":"Kountouras","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"key20240227085737_b41-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/j.gastro.2009.05.044","article-title":"Stem cells and liver regeneration","volume":"137","author":"Duncan","year":"2009","journal-title":"Gastroenterology"},{"key":"key20240227085737_b42-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"key20240227085737_b43-ETM-27-3-12387","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.3748\/wjg.v22.i29.6742","article-title":"Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review","volume":"22","author":"Severson","year":"2016","journal-title":"World J Gastroenterol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T01:57:44Z","timestamp":1708999064000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2024.12387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,15]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2024.12387","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"99"}}